LUX-Lung 7: is there enough data for a final conclusion? – Author's reply
-
Published:2016-07
Issue:7
Volume:17
Page:e268-e269
-
ISSN:1470-2045
-
Container-title:The Lancet Oncology
-
language:en
-
Short-container-title:The Lancet Oncology
Reference5 articles.
1. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial;Park;Lancet Oncol,2016
2. AZD9291, A mutant-selective EGFR inhibitor, as first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): results from a phase 1 expansion cohort;Ramalingam;J Clin Oncol,2015
3. BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M+ NSCLC: Efficacy and safety at the RP2D;Park;J Clin Oncol,2016
4. The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients;Wu;Oncotarget,2016
5. The Allelic context of the C797S Mutation acquired upon treatment with third-generation EGFR Inhibitors impacts sensitivity to subsequent treatment strategies;Niederst;Clin Cancer Res,2015